Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$296.52 -0.2%	$282.95	$253.30 ▼ $346.85	$159.70B	0.49	2.85 million shs	2.10 million shs
AZN AstraZeneca	$70.82 +1.1%	$70.72	$61.24 ▼ $87.68	$217.15B	0.37	5.27 million shs	3.67 million shs
CSLLY CSL	$80.15 -0.5%	$79.02	$70.22 ▼ $109.00	$78.01B	0.79	73,281 shs	35,518 shs
GILD Gilead Sciences	$113.24 +2.0%	$107.40	$67.65 ▼ $119.96	$138.15B	0.29	7.70 million shs	5.23 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+1.38%	+2.23%	+2.30%	+2.03%	-4.64%
AZN AstraZeneca	+0.56%	-2.02%	-3.92%	+4.88%	-9.22%
CSLLY CSL	+0.19%	+2.30%	+2.01%	+3.95%	-19.37%
GILD Gilead Sciences	-0.64%	-0.60%	-1.24%	+5.52%	+64.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.5231 of 5 stars	2.2	2.0	3.3	3.9	4.1	2.5	1.3
AZN AstraZeneca	2.3618 of 5 stars	2.4	3.0	1.7	0.0	2.9	0.0	1.3
CSLLY CSL	0.8854 of 5 stars	0.0	3.0	1.7	0.0	1.0	0.0	1.3
GILD Gilead Sciences	4.7418 of 5 stars	1.4	3.0	4.2	4.1	4.0	2.5	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.35	Hold	$307.82	3.81% Upside
AZN AstraZeneca	2.83	Moderate Buy	$85.00	20.02% Upside
CSLLY CSL	4.00	Strong Buy	N/A	N/A
GILD Gilead Sciences	2.77	Moderate Buy	$111.38	-1.64% Downside

Current Analyst Ratings Breakdown

Latest CSLLY, AZN, AMGN, and GILD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$328.00
6/24/2025	AMGN Amgen	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/24/2025	AMGN Amgen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$305.00
5/21/2025	GILD Gilead Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/20/2025	AMGN Amgen	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$288.00
5/16/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$329.00 ➝ $328.00
5/8/2025	AMGN Amgen	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/7/2025	AMGN Amgen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$235.00 ➝ $280.00
5/2/2025	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$319.00 ➝ $315.00
5/2/2025	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight
5/2/2025	AMGN Amgen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$324.00 ➝ $320.00

(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.77	$30.32 per share	9.78	$10.93 per share	27.13
AZN AstraZeneca	$54.07B	4.06	$6.37 per share	11.12	$13.18 per share	5.37
CSLLY CSL	$14.80B	5.24	$3.96 per share	20.25	$20.07 per share	3.99
GILD Gilead Sciences	$28.75B	4.90	$7.00 per share	16.17	$15.44 per share	7.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$10.96	27.05	13.86	2.69	17.39%	176.11%	12.39%	8/5/2025 (Estimated)
AZN AstraZeneca	$7.04B	$2.49	28.44	14.16	1.29	14.14%	33.14%	12.83%	7/29/2025 (Estimated)
CSLLY CSL	$2.64B	N/A	0.00	19.60	1.74	N/A	N/A	N/A	8/19/2025 (Estimated)
GILD Gilead Sciences	$480M	$4.75	23.84	13.96	0.72	20.76%	51.93%	17.40%	8/6/2025 (Estimated)

Latest CSLLY, AZN, AMGN, and GILD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	AMGN Amgen	$5.21	N/A	N/A	N/A	$8.86 billion	N/A
7/29/2025	Q2 2025	AZN AstraZeneca	$1.11	N/A	N/A	N/A	$14.08 billion	N/A
5/1/2025	Q1 2025	AMGN Amgen	$4.18	$4.90	+$0.72	$3.20	$8.05 billion	$8.15 billion
4/29/2025	Q1 2025	AZN AstraZeneca	$1.10	$1.24	+$0.14	$0.93	$13.71 billion	$13.59 billion
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.77	$1.81	+$0.04	$1.04	$6.77 billion	$6.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.21%	N/A	86.86%	14 Years
AZN AstraZeneca	$2.06	2.91%	N/A	82.73%	N/A
CSLLY CSL	$1.20	1.50%	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.79%	N/A	66.53%	10 Years

Latest CSLLY, AZN, AMGN, and GILD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2025	GILD Gilead Sciences	quarterly	$0.79	3%	6/13/2025	6/13/2025	6/27/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	8.70	1.17	0.88
AZN AstraZeneca	0.65	0.90	0.70
CSLLY CSL	0.45	1.86	0.85
GILD Gilead Sciences	1.16	1.37	1.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
AZN AstraZeneca	20.35%
CSLLY CSL	0.03%
GILD Gilead Sciences	83.67%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.76%
AZN AstraZeneca	N/A
CSLLY CSL	N/A
GILD Gilead Sciences	0.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	537.71 million	533.62 million	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
CSLLY CSL	32,698	968.42 million	N/A	Not Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable

CSLLY, AZN, AMGN, and GILD Headlines

Recent News About These Companies

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

4 hours ago | zacks.com

Gilead Sciences to Deliver HIV Prevention Drug to Low-Income Countries

5 hours ago | devdiscourse.comD

Gilead finalizes Global Fund deal to accelerate access to lenacapavir for HIV prevention

5 hours ago | thepharmaletter.comT

Gilead in pact to speed up access to new HIV therapy in low-income nations

5 hours ago | msn.com

Gilead, Global Fund Enter Agreement To Supply HIV Prevention Drug To Low & Lower-Middle-Income Countries

5 hours ago | msn.com

Gilead Sciences (NasdaqGS:GILD) Partners With Global Fund To Supply HIV Prevention Drug

5 hours ago | finance.yahoo.com

Gilead Sciences, Inc. (GILD) Reports Advances in HIV Treatment with Phase 2/3 Clinical Trial Update

5 hours ago | msn.com

AHF: Gilead's Greed Costs Latin America HIV Protection

July 9 at 4:37 PM | businesswire.com

Gilead Sciences (GILD) Boosts Global Access to HIV Therapy Lenacapavir

July 9 at 12:16 PM | gurufocus.com

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

July 9 at 10:41 AM | zacks.com

Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet

July 9 at 10:30 AM | zacks.com

Nisa Investment Advisors LLC Cuts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

July 9 at 10:01 AM | marketbeat.com

Lbp Am Sa Has $23 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

July 9 at 9:29 AM | marketbeat.com

Slagle Financial LLC Has $262,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

July 9 at 8:58 AM | marketbeat.com

Gilead, Global Fund finalize plan to supply HIV prevention drug to poor countries

July 9 at 8:16 AM | reuters.com

M&T Bank Corp Decreases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

July 9 at 6:45 AM | marketbeat.com

Stratos Wealth Partners LTD. Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

July 9 at 6:28 AM | marketbeat.com

Envestnet Asset Management Inc. Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD)

July 9 at 5:32 AM | marketbeat.com

Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?

July 8 at 10:56 AM | zacks.com

Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

July 8 at 10:40 AM | zacks.com

Gilead Sciences, Inc. (NASDAQ:GILD) Stake Boosted by DekaBank Deutsche Girozentrale

July 8 at 10:15 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSLLY, AZN, AMGN, and GILD Company Descriptions

Amgen NASDAQ:AMGN

$296.52 -0.48 (-0.16%)

Closing price 04:00 PM Eastern

Extended Trading

$294.98 -1.54 (-0.52%)

As of 07:59 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

AstraZeneca NASDAQ:AZN

$70.82 +0.80 (+1.14%)

Closing price 04:00 PM Eastern

Extended Trading

$70.82 0.00 (0.00%)

As of 07:59 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

CSL OTCMKTS:CSLLY

$80.15 -0.40 (-0.50%)

As of 03:54 PM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Gilead Sciences NASDAQ:GILD

$113.24 +2.18 (+1.96%)

Closing price 04:00 PM Eastern

Extended Trading

$113.38 +0.14 (+0.12%)

As of 07:57 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time